JP2005510568A - アリール基が結合したアザポリサイクリック化合物 - Google Patents
アリール基が結合したアザポリサイクリック化合物 Download PDFInfo
- Publication number
- JP2005510568A JP2005510568A JP2003547416A JP2003547416A JP2005510568A JP 2005510568 A JP2005510568 A JP 2005510568A JP 2003547416 A JP2003547416 A JP 2003547416A JP 2003547416 A JP2003547416 A JP 2003547416A JP 2005510568 A JP2005510568 A JP 2005510568A
- Authority
- JP
- Japan
- Prior art keywords
- ring
- disorder
- disease
- pharmaceutically acceptable
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C=*[n]1nnc2c1cccc2 Chemical compound C=*[n]1nnc2c1cccc2 0.000 description 19
- AWBOSXFRPFZLOP-UHFFFAOYSA-N c1cc2n[o]nc2cc1 Chemical compound c1cc2n[o]nc2cc1 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 2
- HPMUOAPZHNPJLW-UHFFFAOYSA-N C1Cc2[n-]c3ccccc3[n]2CC1 Chemical compound C1Cc2[n-]c3ccccc3[n]2CC1 HPMUOAPZHNPJLW-UHFFFAOYSA-N 0.000 description 1
- QHDDBWGHEWTMDV-UHFFFAOYSA-N C1Cc2nc3ccccc3[n]2CC1 Chemical compound C1Cc2nc3ccccc3[n]2CC1 QHDDBWGHEWTMDV-UHFFFAOYSA-N 0.000 description 1
- YVSALFTUYBPYQI-UHFFFAOYSA-N CCc1n[o]c2ccccc12 Chemical compound CCc1n[o]c2ccccc12 YVSALFTUYBPYQI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
- C07H7/033—Uronic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33450201P | 2001-11-30 | 2001-11-30 | |
| PCT/IB2002/004820 WO2003045967A1 (en) | 2001-11-30 | 2002-11-18 | Aryl fused azapolycyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005510568A true JP2005510568A (ja) | 2005-04-21 |
| JP2005510568A5 JP2005510568A5 (enExample) | 2008-08-14 |
Family
ID=23307510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547416A Pending JP2005510568A (ja) | 2001-11-30 | 2002-11-18 | アリール基が結合したアザポリサイクリック化合物 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6858624B2 (enExample) |
| EP (1) | EP1451202B1 (enExample) |
| JP (1) | JP2005510568A (enExample) |
| KR (1) | KR20040063939A (enExample) |
| CN (1) | CN1596263A (enExample) |
| AR (1) | AR037596A1 (enExample) |
| AT (1) | ATE405574T1 (enExample) |
| AU (1) | AU2002365314A1 (enExample) |
| BR (1) | BR0214578A (enExample) |
| CA (1) | CA2468717A1 (enExample) |
| CO (1) | CO5570673A2 (enExample) |
| DE (1) | DE60228478D1 (enExample) |
| DO (1) | DOP2002000518A (enExample) |
| ES (1) | ES2310626T3 (enExample) |
| GT (1) | GT200200243A (enExample) |
| HN (1) | HN2002000335A (enExample) |
| IL (1) | IL161836A0 (enExample) |
| NO (1) | NO20042214L (enExample) |
| PA (1) | PA8559201A1 (enExample) |
| PE (1) | PE20030724A1 (enExample) |
| PL (1) | PL369886A1 (enExample) |
| PY (1) | PY0228833A (enExample) |
| RU (1) | RU2004116320A (enExample) |
| TW (1) | TW200300346A (enExample) |
| UY (1) | UY27554A1 (enExample) |
| WO (1) | WO2003045967A1 (enExample) |
| ZA (1) | ZA200402994B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE386024T1 (de) * | 1997-12-31 | 2008-03-15 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| EP1578422B1 (en) | 2002-12-20 | 2007-04-11 | NicoNovum AB | A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material |
| US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
| US20090203658A1 (en) * | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| EP2198332A4 (en) * | 2007-09-06 | 2011-11-30 | 3M Innovative Properties Co | LIGHT CONDUCTOR WITH LIGHT EXTRACTION STRUCTURES FOR PROVIDING REGIONAL CONTROL OF LIGHT OUTPUT |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| WO2022147189A1 (en) * | 2020-12-30 | 2022-07-07 | Antares Pharma, Inc. | Varenicline prodrugs |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994011030A1 (en) * | 1992-11-13 | 1994-05-26 | The Ohio State University Research Foundation | C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide |
| AU4394897A (en) | 1996-10-30 | 1998-05-22 | Pfizer Inc. | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and the ir use in addiction therapy |
| US6020335A (en) | 1997-02-06 | 2000-02-01 | Pfizer Inc | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents |
| US5977131A (en) | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| ATE386024T1 (de) | 1997-12-31 | 2008-03-15 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
| US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| EP0955301A3 (en) | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
| KR100420423B1 (ko) | 1998-04-29 | 2004-03-04 | 화이자 프로덕츠 인코포레이티드 | 아릴 축합된 아자 다환식 화합물 |
-
2002
- 2002-11-18 AT AT02803886T patent/ATE405574T1/de not_active IP Right Cessation
- 2002-11-18 IL IL16183602A patent/IL161836A0/xx unknown
- 2002-11-18 JP JP2003547416A patent/JP2005510568A/ja active Pending
- 2002-11-18 KR KR10-2004-7008118A patent/KR20040063939A/ko not_active Abandoned
- 2002-11-18 RU RU2004116320/04A patent/RU2004116320A/ru not_active Application Discontinuation
- 2002-11-18 WO PCT/IB2002/004820 patent/WO2003045967A1/en not_active Ceased
- 2002-11-18 ES ES02803886T patent/ES2310626T3/es not_active Expired - Lifetime
- 2002-11-18 DE DE60228478T patent/DE60228478D1/de not_active Expired - Fee Related
- 2002-11-18 PL PL02369886A patent/PL369886A1/xx not_active Application Discontinuation
- 2002-11-18 CA CA002468717A patent/CA2468717A1/en not_active Abandoned
- 2002-11-18 EP EP02803886A patent/EP1451202B1/en not_active Expired - Lifetime
- 2002-11-18 CN CNA028236289A patent/CN1596263A/zh active Pending
- 2002-11-18 AU AU2002365314A patent/AU2002365314A1/en not_active Abandoned
- 2002-11-18 BR BR0214578-2A patent/BR0214578A/pt not_active IP Right Cessation
- 2002-11-20 PY PY200200228833A patent/PY0228833A/es unknown
- 2002-11-21 DO DO2002000518A patent/DOP2002000518A/es unknown
- 2002-11-25 TW TW091134186A patent/TW200300346A/zh unknown
- 2002-11-27 HN HN2002000335A patent/HN2002000335A/es unknown
- 2002-11-27 GT GT200200243A patent/GT200200243A/es unknown
- 2002-11-27 US US10/306,500 patent/US6858624B2/en not_active Expired - Fee Related
- 2002-11-28 PA PA20028559201A patent/PA8559201A1/es unknown
- 2002-11-28 PE PE2002001146A patent/PE20030724A1/es not_active Application Discontinuation
- 2002-11-28 UY UY27554A patent/UY27554A1/es not_active Application Discontinuation
- 2002-11-28 AR ARP020104596A patent/AR037596A1/es unknown
-
2004
- 2004-04-20 ZA ZA200402994A patent/ZA200402994B/en unknown
- 2004-04-26 CO CO04037673A patent/CO5570673A2/es not_active Application Discontinuation
- 2004-05-27 NO NO20042214A patent/NO20042214L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE405574T1 (de) | 2008-09-15 |
| NO20042214D0 (no) | 2004-05-27 |
| GT200200243A (es) | 2003-06-25 |
| PE20030724A1 (es) | 2003-08-28 |
| KR20040063939A (ko) | 2004-07-14 |
| IL161836A0 (en) | 2005-11-20 |
| AR037596A1 (es) | 2004-11-17 |
| CA2468717A1 (en) | 2003-06-05 |
| US6858624B2 (en) | 2005-02-22 |
| EP1451202B1 (en) | 2008-08-20 |
| PL369886A1 (pl) | 2005-05-02 |
| US20030166582A1 (en) | 2003-09-04 |
| BR0214578A (pt) | 2004-11-03 |
| TW200300346A (en) | 2003-06-01 |
| ES2310626T3 (es) | 2009-01-16 |
| EP1451202A1 (en) | 2004-09-01 |
| NO20042214L (no) | 2004-05-27 |
| UY27554A1 (es) | 2003-06-30 |
| WO2003045967A1 (en) | 2003-06-05 |
| ZA200402994B (en) | 2005-04-20 |
| DOP2002000518A (es) | 2003-05-31 |
| CO5570673A2 (es) | 2005-10-31 |
| PY0228833A (es) | 2004-06-01 |
| CN1596263A (zh) | 2005-03-16 |
| DE60228478D1 (de) | 2008-10-02 |
| AU2002365314A1 (en) | 2003-06-10 |
| HN2002000335A (es) | 2003-01-10 |
| RU2004116320A (ru) | 2005-10-10 |
| PA8559201A1 (es) | 2003-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2258652T3 (es) | Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos. | |
| JP2656700B2 (ja) | 置換キヌクリジン誘導体 | |
| US20230140635A1 (en) | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | |
| EP2129224B1 (en) | 5,6-dihydro-1h-pyridin-2-one compounds | |
| KR101325324B1 (ko) | 인지 장애 치료용 키트, 조성물, 제품 또는 의약 | |
| JP3948026B2 (ja) | 脳細胞保護剤 | |
| PT2081929E (pt) | Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados | |
| JPH06500124A (ja) | セロトニン作動性５―ｈｔ３拮抗薬として新規イミダゾピリジン | |
| US20010006972A1 (en) | Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome | |
| CA2893256A1 (en) | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 | |
| WO2023137453A1 (en) | Prodrugs of 3,4-methylenedioxy-n-methcathinone and uses thereof | |
| EP1451202B1 (en) | Aryl fused azapolycyclic compounds | |
| FI97544C (fi) | Menetelmä lääkeaineina käyttökelpoisten 1-(pyrido/3,4-b/-1,4-oksatsin-4-yyli)-1H-indolien valmistamiseksi | |
| JPS6216952B2 (enExample) | ||
| JP2002502403A (ja) | ベンゾナフチリジン | |
| EP1648893B1 (en) | Nicotine addiction reducing heteroaryl fused azapolycyclic compounds | |
| BG63710B1 (bg) | Ентерокинетични бензамиди | |
| JP2008056700A (ja) | 精神障害及び眼障害の治療用ｓ−メチル−ジヒドロ−ジプラシドン | |
| CN121226319A (zh) | 烯基取代的哌啶类化合物及其药物组合物、制备方法和用途 | |
| Kim et al. | Probes for narcotic receptor mediated phenomena. 15.(3S, 4S)-(+)-trans-3-Methylfentanyl isothiocyanate, a potent site-directed acylating agent for the. delta.-opioid receptors in vitro | |
| EP1824852B1 (en) | 1,2,3,3a,8,8a-hexahydro-2,7a-diaza-cyclopenta[a]inden-7-one derivatives which bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function and in the treatment of addictive disorders | |
| HK1070660A (en) | Aryl fused azapolycyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20071003 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071003 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080310 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080313 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080610 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080617 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080627 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080723 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090608 |